Application | Comment | Organism |
---|---|---|
synthesis | stepwise enzymatic synthesis of human blood group B antigen tetrasaccharide. Biosynthetic pathway of B antigen is the same in Escherichia coli O86 as in humans, thus providing us an attractive way of synthesizing blood group B antigen with microbial glycosyltransferases | Escherichia coli |
Cloned (Comment) | Organism |
---|---|
expressed in Escherichia coli as a GST-tagged fusion protein | Escherichia coli |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Escherichia coli | Q58YV9 | - |
- |
Escherichia coli O86 | Q58YV9 | - |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
GDP-beta-L-fucose + beta-D-Gal-(1->3)-alpha-D-GalNAc-OMe | - |
Escherichia coli | GDP + alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-alpha-D-GalNAc-OMe | - |
? | |
GDP-beta-L-fucose + beta-D-Gal-(1->3)-alpha-D-GalNAc-OMe | - |
Escherichia coli O86 | GDP + alpha-L-Fuc-(1->2)-beta-D-Gal-(1->3)-alpha-D-GalNAc-OMe | - |
? | |
GDP-beta-L-fucose + beta-D-Gal-OMe | 15% of the activity compared to beta-Gal-(1->3)-alpha-GalNAc-OMe | Escherichia coli | ? | - |
? | |
GDP-beta-L-fucose + beta-D-Gal-OMe | 15% of the activity compared to beta-Gal-(1->3)-alpha-GalNAc-OMe | Escherichia coli O86 | ? | - |
? | |
additional information | WbnK requires a terminal beta-1,3-linked Gal sugar sequence as acceptor | Escherichia coli | ? | - |
? | |
additional information | WbnK requires a terminal beta-1,3-linked Gal sugar sequence as acceptor | Escherichia coli O86 | ? | - |
? |
Synonyms | Comment | Organism |
---|---|---|
WbnK | - |
Escherichia coli |